

Biosimilares: una oportunidad para adelantar tratamientos

José Manuel Carrascosa


Servicio de Dermatología

Hospital Universitario Germans Trias. IGTP. UAB

Badalona

→ Number of patients under biologic therapy for psoriasis, including biosimilar; cost per patient and total cost per year. 2010-2020.

Year	N patients	cost/year	cost/patient
2010	25	327.815,78	13.112,63
2011	54	440.068,42	8.149,42
2012	93	666.010,44	7.161,40
2013	84	582.305,12	6.932,20
2014	115	805.829,18	7.007,21
2015	124	877.513,05	7.076,71
2016	150	1.145.297,02	7.635,31
2017	192	1.459.180,39	7.599,89
2018	230	1.443.218,33	6.274,86
2019	310	1.555.697,36	5.018,37
2020	349	1.519.610,12	4.354,18




Biosimilares: han permitido adelantar el uso de biológico

Table 1. Clinical and demographic features of patients included in the study


	All patients (n = 89)	Biosimilar (n = 41)	Biologic (n = 48)	p-value
Age (years), mean (SD)	51.5 (13)	48 (12)	55 (15)	0.030* ←
Weight (kg), mean (SD)	83.5 (18)	82 (18)	85 (17)	0.430
BMI (kg/m²), mean (SD)	28.6 (5)	27.7 (5)	29.4 (6)	0.197
Sex				
Men (%)	55 (61.8)	25 (61)	30 (62.5)	0.929
Women (%)	34 (38.2)	16 (39)	18 (37.5)	
Psoriatic arthritis, n (%)	28 (31.5)	13 (31.7)	15 (31.3)	0.863
Previous treatment with biologic agents, n(%)	17 (19)	5 (12.5)	12 (25)	0.225

Drug survival differences between adalimumab original and biosimilar in patients with moderate to severe psoriasis: a different management for the same drug? D. Pesqué, J. Escobar, X. Fernandez, M. Ferran, F. Gallardo. (under review)

→ **Ratio cost/PASI90** per year, per therapeutic group



Intercepción precoz de la PsA



Nomenclature for research and prevention/interception trials in people with PsO at risk of PsA	
Phase	Definition
A. At higher risk	People with PsO at higher risk of PsA (i.e., severe skin involvement, nail involvement, obesity, familial history) of PsA.*
B. Sub-clinical	People with PsO with arthralgia and/or imaging evidence of synovial/enthesal inflammation without clinical synovitis
C. Clinical	People with PsO and clinical synovitis

CLINICAL SCIENCE

EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis


Alen Zabotti ¹, Gabriele De Marco, ^{2,3} Laure Gossec, ^{4,5} Xenofon Baraliakos, Daniel Aletaha, ⁷ Annamaria Iagnocco, ⁸ Paolo Gisondi, ⁹ Peter V Balint, ¹⁰ Heidi Bertheussen, ¹¹ Woll-Henning Boehncke, ¹² Nemanja S Damjanov, ¹³ Maarten de Wit, ¹⁴ Enzo Errichetti, ¹⁵ Helena Marzo-Ortega, ^{2,3} Mikhail Protopopov, ¹⁶ Lluis Puig, ¹⁷ Rubén Queiro, ¹⁸ Piero Ruscitti, ¹⁹ Laura Savage, ²⁰ Georg Schett, ²¹ Stefan Siebert, ²² Tanja A Stamm, ²³ Paul Studenic, ⁷ Ilaria Tinazzi, ²⁴ Filip E Van den Bosch, ²⁵ Annette van der Helm-van Mil, ^{26,27} Abdulla Watad, ²⁸ Josef S Smolen, ⁷ Dennis G McGonagle ^{2,3}



Germans Trias i Pujol
Hospital

Zabotti A, et al. *Ann Rheum Dis* 2023;0:1–9. doi:10.1136/ard-2023-224148

The "SCAR" of patient burden over the life span¹⁻³



Psoriasis is associated with significant physical, psychological, social, and economic burden, the cumulative effect of which may result in failure to achieve 'full life potential' in some patients, termed 'cumulative life course impairment'. In this concept, the burden of stigmatization, and physical and psychological comorbidities (risk factors for cumulative impairment) and coping strategies and external factors (having potential moderating effects), interact to cause lifetime impairment.⁴

BSA, body surface area; CRP, C-reactive protein; CV, cardiovascular; MetS, metabolic syndrome; PASI, Psoriasis Area Severity Index; PGA, Physician's Global Assessment; PsA, psoriatic arthritis.

1. Smith C, et al. *Br J Dermatol* 2017;177:628–36; 2. Menter A, et al. *J Am Acad Dermatol* 2019;80:1029–72; 3. Amatore F, et al. *J Eur Acad Dermatol Venereol* 2019;33:464–83; 4. Kimball A, et al. *J Eur Acad Dermatol Venereol* 2010;24:989–1004.